WCLC Updates in Neoadjuvant Therapy for NSCLC

Experts in thoracic oncology discuss the role of single-agent immunotherapy as neoadjuvant therapy and comment on the viability of MPR [major pathologic response] as a surrogate endpoint for non–small cell lung cancer (NSCLC).

Related Videos
View All
Related Content